THERMO FISHER SCIENTIFIC INC.

TMO

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Rock Springs Capital OrbiMed Advisors

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 10,000Value: $5.8M

# Signal Note: Rock Springs Capital Initiates TMO Position **Summary:** Rock Springs Capital's $5.8M long position in Thermo Fisher reflects confidence in TMO's lab services and instrumentation franchise, likely ahead of potential M&A activity or margin expansion from AI-driven drug discovery tools. The 10k share entry suggests conviction in near-term catalysts, possibly tied to biotech funding cycles or large pharma outsourcing acceleration, though no specific pipeline catalyst is immediately apparent.

OrbiMed AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

MLYS2 funds NBIX2 funds APLS2 funds FOLD2 funds BCAX2 funds ARGX2 funds OCUL2 funds JANX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: OrbiMed Initiates $26.9M TMO Position OrbiMed's new 46,500-share stake in Thermo Fisher likely reflects conviction in TMO's life sciences tools and services exposure to biotech funding cycles and clinical trial activity. The position timing may signal confidence in near-term pharma/biotech spending recovery, though the broad-based tools platform provides diversified upside across multiple end-markets rather than single-catalyst optionality. No specific pipeline catalyst identified; this appears to be a core portfolio allocation to a sector infrastructure play.